Verastem, Inc. (VSTM): Price and Financial Metrics

Verastem, Inc. (VSTM): $8.13

0.19 (-2.28%)

POWR Rating

Component Grades

Momentum

F

Stability

D

Sentiment

Quality

C

Add VSTM to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#179 of 356

in industry

VSTM Price/Volume Stats

Current price $8.13 52-week high $15.18
Prev. close $8.32 52-week low $3.47
Day low $7.83 Volume 157,300
Day high $8.47 Avg. volume 184,845
50-day MA $9.84 Dividend yield N/A
200-day MA $7.44 Market Cap 205.29M

VSTM Stock Price Chart Interactive Chart >


Verastem, Inc. (VSTM) Company Bio


Verastem, Inc. focuses on discovering and developing drugs for the treatment of cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. The company was founded in 2010 and is based in Needham, Massachusetts.


VSTM Latest News Stream


Event/Time News Detail
Loading, please wait...

VSTM Latest Social Stream


Loading social stream, please wait...

View Full VSTM Social Stream

Latest VSTM News From Around the Web

Below are the latest news stories about VERASTEM INC that investors may wish to consider to help them evaluate VSTM as an investment opportunity.

Verastem Presents Avutometinib and Defactinib Combination Program Updates at the 5th Annual RAS-Targeted Drug Development Summit

BOSTON, September 28, 2023--Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the presentation of scientific background and clinical trial updates on the avutometinib and defactinib programs at the 5th Annual RAS-Targeted Drug Development Summit in Boston, Massachusetts. The updates are part of two oral presentations by Jonathan Pachter, PhD, Chief Scientific Officer and Louis Denis, MD, Chief Medical Off

Yahoo | September 28, 2023

Verastem Oncology to Participate in Upcoming Investor Conferences

BOSTON, September 05, 2023--Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that the Company will participate in the following upcoming investor conferences:

Yahoo | September 5, 2023

3 Penny Stocks That Can Triple Your Money in the Next 12 Months

Although penny stocks are among the most speculative asset classes, these wagers just happen to have strong analyst backing.

Josh Enomoto on InvestorPlace | September 4, 2023

Verastem Oncology Enters Discovery and Development Collaboration with GenFleet Therapeutics to Advance New Programs Targeting RAS Pathway-Driven Cancers

BOSTON, August 28, 2023--Verastem Oncology (Nasdaq: VSTM) (the "Company"), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that the Company has entered into a discovery and development collaboration with GenFleet Therapeutics ("GenFleet") to advance three oncology discovery programs targeting RAS pathway-driven cancers.

Yahoo | August 28, 2023

Verastem Oncology Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress

BOSTON, August 08, 2023--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the second quarter ending June 30, 2023 and highlighted recent progress.

Yahoo | August 8, 2023

Read More 'VSTM' Stories Here

VSTM Price Returns

1-mo -17.55%
3-mo 4.90%
6-mo 93.57%
1-year -20.29%
3-year -46.23%
5-year -89.84%
YTD 68.32%
2022 -80.37%
2021 -3.76%
2020 58.96%
2019 -60.12%
2018 9.45%

Continue Researching VSTM

Here are a few links from around the web to help you further your research on Verastem Inc's stock as an investment opportunity:

Verastem Inc (VSTM) Stock Price | Nasdaq
Verastem Inc (VSTM) Stock Quote, History and News - Yahoo Finance
Verastem Inc (VSTM) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!